Ellen Cavaleri
Investor Relations Contact en LYRA THERAPEUTICS, INC. .
Perfil
Ms. Ellen Cavaleri is a Senior VP-Investor Relations & Communications at Lyra Therapeutics, Inc. Ms. Cavaleri was previously employed as an Investor Relations Contact by Kadmon Holdings, Inc. She received her undergraduate degree from Vanderbilt University and an MBA from New York University.
Cargos activos de Ellen Cavaleri
Empresas | Cargo | Inicio |
---|---|---|
LYRA THERAPEUTICS, INC. | Investor Relations Contact | 01/01/2022 |
Antiguos cargos conocidos de Ellen Cavaleri.
Empresas | Cargo | Fin |
---|---|---|
KADMON HOLDINGS, INC. | Investor Relations Contact | - |
Formación de Ellen Cavaleri.
Vanderbilt University | Undergraduate Degree |
New York University | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
LYRA THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 1 |
---|---|
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Ellen Cavaleri